BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-71@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Innovent Biologics (Suzhou) Co. Ltd. — Irinotecan OR Pac
 litaxel or Trifluridine/tipiracil（ FTD/TPI） [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Multicenter\, Phase 3 Study of IB
 I343 Monotherapy Versus Treatment of Investigator's Choice in Subjects Wit
 h Previously Treated\, Claudin (CLDN) 18.2-positive\, HER2-negative\, Gast
 ric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001).\nSource: htt
 ps://clinicaltrials.gov/study/NCT06238843\nhttps://catalystbrief.girapphe.
 com/e/71?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/71?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
